This is a report of our experience with percutaneous, MRI-guided biopsies in 25 patients with skeletal lesions using a 1.5-T MR hybrid system. Twenty-five consecutive patients with skeletal lesions were referred for MRI-guided biopsy. Biopsies were performed with a 1.5-T Philips Gyroscan (Philips Medical Systems, Best, The Netherlands) combined with a c-arm fluoroscopy. Specimens were obtained percutaneously either with a 14- or 18-gauge "side-slit" type of biopsy needle (n = 10 skeletal lesions that had penetrated through the cortex), or using a prototype coaxial drill system powered either by hand or an optional motor (n = 15 skeletal lesions still covered with cortical bone). All but two biopsies could be completed within the MR unit. For one patient, who required a transpedicular approach to a lumbar vertebra, and for one child, who required general anesthesia, we decided to switch to CT guidance. In 19 of the 25 cases (17 of the 23 cases performed in MR), the sample was sufficient and the histopathologic diagnosis was confirmed. Three patients had an inadequate sample, and three others had adequate samples but inaccurate results. No procedural complications occurred. Percutaneous biopsy of skeletal lesions performed under MRI-guidance was found to be safe and reasonably accurate. There were no procedural complications in our small series. MRI may be used as an alternative to CT, but its role vis-à-vis CT has yet to be ascertained.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.1880080118DOI Listing

Publication Analysis

Top Keywords

skeletal lesions
20
mri-guided biopsy
8
hybrid system
8
patients skeletal
8
procedural complications
8
skeletal
5
lesions
5
biopsy bone
4
bone hybrid
4
system report
4

Similar Publications

. CXCR4 is a chemokine receptor that is frequently overexpressed in invasive breast cancer and plays a major role in tumor proliferation, aggressiveness and metastasis. The aim of this prospective study was to establish the value of CXCR4-directed PET imaging in patients with breast cancer using the novel CXCR4-targeted PET probe Ga-Pentixafor by comparing it with F-FDG PET/CT ( = 40).

View Article and Find Full Text PDF

Purpose: The proximal femur is a frequent site of cancer dissemination in the extremities. Patients treated surgically for skeletal metastases have poorer overall health compared to other orthopedic patients, with only one-third expected to survive two years post-surgery. Choosing a treatment that minimizes revision risk and ensures the implant outlives the patient is therefore crucial.

View Article and Find Full Text PDF

Background: Olfactory neuroblastoma (ONB) is a rare malignancy that develops in the nasal cavity, with appendicular skeletal metastases being exceptionally uncommon. We report the case of a middle-aged male with ONB, presenting with an unusual biopsy-confirmed solitary metastasis to the left proximal femur.

Case Presentation: A 33-year-old male was previously diagnosed with olfactory neuroblastoma in the skull base after initial clinical presentation with progressive left-sided nasal obstruction for six months.

View Article and Find Full Text PDF

Fibroblast activation protein (FAP)-targeted radionuclides are known as a promising step in cancer diagnosis and treatment (theranostic), although it is still a subject under investigation. We present a patient with anaplastic thyroid carcinoma who underwent 99mTc-FAPI-46 SPECT/CT for the evaluation of metastatic disease. Several metastatic sites were found with considerable 99mTc-FAPI-46 uptake.

View Article and Find Full Text PDF

Pyomyositis is a subacute bacterial infection of the skeletal muscle that is more common in the tropics. is the most common pathogen involved in pyomyositis, but (group B (GBS)) can cause pyomyositis. We herein present a case of pyomyositis of the right gluteus maximus caused by GBS bacteremia (primary bacteremia).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!